A low serum IGF-1 is correlated with sarcopenia in subjects with type 1 diabetes mellitus: Findings from a post-hoc analysis of the iDIAMOND study

• Published in: Diabetes research and clinical practice Vol. 179; p. 108998
• Main Authors: Hata, Sonyun, Mori, Hiroyasu, Yasuda, Tetsuyuki, Irie, Yoko, Yamamoto, Tsunehiko, Umayahara, Yutaka, Ryomoto, Kayoko, Yoshiuchi, Kazutomi, Yoshida, Sumiko, Shimomura, Iichiro, Kuroda, Akio, Matsuhisa, Munehide
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.09.2021
• Subjects: Cross-Sectional Studies; Diabetes Mellitus, Type 1 - complications; Diabetes Mellitus, Type 1 - pathology; Hand Strength; Humans; Insulin-Like Growth Factor I - metabolism; Muscle, Skeletal - pathology; Sarcopenia; Sarcopenia - epidemiology; Sarcopenia - etiology; Sarcopenia - pathology; Serum IGF-1; Skeletal muscle mass; Type 1 diabetes; Sarcopenia; Skeletal muscle mass; Type 1 diabetes; Serum IGF-1
• ISSN: 0168-8227; 1872-8227; 1872-8227
• DOI: 10.1016/j.diabres.2021.108998

•The factors associated with sarcopenia in type 1 diabetes (T1DM) have not been clarified.•IGF-1 plays a crucial role in skeletal muscle growth, differentiation, and regeneration.•The z-score of IGF-1 was significantly lower in T1DM than non-T1DM.•The z-score of IGF-1 was associated with sarcopenia and a low skeletal muscle mass in T1DM. Our previous study revealed that sarcopenia was frequently observed in subjects with type 1 diabetes mellitus (T1DM). However, the factors associated with sarcopenia that are related to T1DM have not yet been clarified. Insulin-like growth factor-1 (IGF-1) has been shown to play a role in skeletal muscle growth, differentiation, and regeneration. The present study, therefore, investigated the association between the serum IGF-1 level and sarcopenia and low skeletal muscle mass in subjects with T1DM. This cross-sectional study enrolled subjects with T1DM (n = 168) and without diabetes (n = 59) who had had their clinical data on serum IGF-1 collected in the iDIAMOND study. The z-score of serum IGF-1 was significantly lower in the subjects with T1DM than that in those without diabetes (p < 0.001). Among subjects with T1DM, the z-score of serum IGF-1 was significantly lower in sarcopenic subjects than in non-sarcopenic subjects. The multivariable logistic regression analysis showed that the serum IGF-1 z-score was an independent determinant of sarcopenia and a low skeletal muscle mass index, but not low grip strength nor slow gait speed in subjects with T1DM. A low serum IGF-1 level is correlated with sarcopenia and low skeletal muscle mass in subjects with T1DM.